Boston Common Asset Management LLC grew its holdings in shares of Amgen, Inc. (NASDAQ:AMGN) by 20.6% during the second quarter, HoldingsChannel reports. The institutional investor owned 13,870 shares of the medical research company’s stock after purchasing an additional 2,365 shares during the quarter. Boston Common Asset Management LLC’s holdings in Amgen were worth $2,560,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of AMGN. Braun Bostich & Associates Inc. bought a new position in shares of Amgen in the 1st quarter worth $113,000. WealthTrust Fairport LLC bought a new position in shares of Amgen in the 1st quarter worth $121,000. Cornerstone Advisors Inc. lifted its holdings in shares of Amgen by 76.5% in the 1st quarter. Cornerstone Advisors Inc. now owns 729 shares of the medical research company’s stock worth $124,000 after purchasing an additional 316 shares in the last quarter. Gables Capital Management Inc. bought a new position in shares of Amgen in the 1st quarter worth $174,000. Finally, Mount Yale Investment Advisors LLC bought a new position in shares of Amgen in the 1st quarter worth $181,000. Hedge funds and other institutional investors own 80.04% of the company’s stock.

In other news, EVP Sean E. Harper sold 1,525 shares of the firm’s stock in a transaction on Tuesday, June 12th. The stock was sold at an average price of $184.27, for a total transaction of $281,011.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 0.27% of the company’s stock.

AMGN has been the topic of a number of recent research reports. Cann reiterated a “buy” rating on shares of Amgen in a report on Friday, June 8th. Citigroup increased their target price on Amgen from $188.00 to $200.00 and gave the stock a “neutral” rating in a report on Monday, July 30th. Robert W. Baird increased their target price on Amgen from $165.00 to $179.00 and gave the stock a “neutral” rating in a report on Monday, July 30th. Mizuho reiterated a “buy” rating and issued a $200.00 target price on shares of Amgen in a report on Friday, June 22nd. Finally, Morgan Stanley raised their price objective on Amgen from $200.00 to $210.00 and gave the company a “buy” rating in a research note on Friday, July 13th. One analyst has rated the stock with a sell rating, twelve have assigned a hold rating and twelve have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $202.76.

Shares of NASDAQ:AMGN opened at $197.42 on Friday. The company has a current ratio of 3.39, a quick ratio of 3.12 and a debt-to-equity ratio of 2.03. Amgen, Inc. has a 1-year low of $163.31 and a 1-year high of $201.23. The firm has a market cap of $125.84 billion, a price-to-earnings ratio of 15.69, a P/E/G ratio of 1.90 and a beta of 1.36.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Thursday, July 26th. The medical research company reported $3.83 earnings per share for the quarter, beating the consensus estimate of $3.52 by $0.31. Amgen had a return on equity of 43.18% and a net margin of 10.19%. The business had revenue of $6.06 billion for the quarter, compared to analysts’ expectations of $5.73 billion. During the same period last year, the business earned $3.27 EPS. The business’s revenue was up 4.3% on a year-over-year basis. sell-side analysts forecast that Amgen, Inc. will post 13.95 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 7th. Stockholders of record on Friday, August 17th will be given a dividend of $1.32 per share. This represents a $5.28 annualized dividend and a dividend yield of 2.67%. The ex-dividend date is Thursday, August 16th. Amgen’s dividend payout ratio is presently 41.97%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.

Further Reading: Understanding Stock Ratings

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.